Will EFU Health and Jubilee General and Adamjee Insurance cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Anktiva is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by DRAP?

The DRAP named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; DRAP review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Pakistani-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. Pakistan Medical and Dental Council (PMDC) and DRAP verifies the active license; the DRAP application records both the prescribing physician and the dispensing facility.

Can I receive Anktiva at home?

The dispensing facility must be Pakistani-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative quote provided at intake. Delivered quote within 24h.Get my quote

Anktiva access in Pakistan: the DRAP named-patient pathway

How patients in the Islamic Republic of Pakistan legally obtain Anktiva (nogapendekin alfa inbakicept-pmln) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Pakistan access Anktiva (nogapendekin alfa inbakicept-pmln) for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumours, in adults, given with BCG through the DRAP named-patient pathway, a Drug Regulatory Authority of Pakistan-administered mechanism that allows a Pakistani-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in PKR.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Anktiva reaches patients in Pakistan

Anktiva (nogapendekin alfa inbakicept-pmln, an IL-15 receptor superagonist fusion protein from ImmunityBio, FDA-approved 22 April 2024 in combination with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumours) is not currently visible on the DRAP registered-product verification portal at dra.gov.pk/e-services/online-data-verification as of 2026-06-01. Patients access Anktiva under the Special Permission for Import of Therapeutic Goods for Personal Use (the patient-named No Objection Certificate or NOC), administered by the Import and Export Section of the DRAP Quality Assurance and Laboratory Testing Division under the Drugs Act 1976 read with the Drugs (Import and Export) Rules 1976 and DRAP Guidance Document QALT/GL/IP/004 at dra.gov.pk Guidance. The application is filed online via the DRAP Special Permissions portal at dra.gov.pk Special Permissions. DRAP does not publish a fixed processing-time SLA; patient-org reporting indicates several working days when documentation is complete. For Anktiva specifically, the clinical justification must reference cystoscopy and biopsy confirmation of high-grade non-muscle invasive bladder cancer with carcinoma in situ, documented BCG-unresponsive disease per the FDA definition (persistent or recurrent CIS within 12 months of adequate BCG induction plus maintenance), the planned Anktiva plus BCG intravesical induction and maintenance schedule per the QUILT-3.032 phase 2 trial protocol (NCT03022825), the cystoscopic surveillance plan, and patient counselling on radical cystectomy as the alternative. The prescribing urologic oncologist must be registered with the Pakistan Medical and Dental Council. The NOC is single-consignment for the induction or maintenance cycle scaled to roughly three months of supply per the DRAP guidance convention; chronic urology maintenance therapy requires re-filing each shipment cycle. A parallel hospital-led pathway under the Special Permission for Institutional Import framework allows institutional importers to file on the prescribing physician's behalf.

Where Anktiva is dispensed in Pakistan

Site selection for Anktiva turns on a much shorter capability checklist than cell therapy: a urologist comfortable with cystoscopic intravesical instillation, a day-case bladder-instillation suite, refrigerated pharmacy storage at 2 to 8 degrees Celsius with continuous logging, and a co-administration plan for intravesical BCG. No certified-cell-therapy infrastructure, no lymphodepletion ward, and no ICU bed are required. The natural dispensing home in Pakistan is therefore the urology service rather than the medical-oncology service. The Sindh Institute of Urology and Transplantation in Karachi (siut.org) is the dominant referral node nationally; it runs the largest public urologic oncology programme in the country, performs high BCG-instillation volume, and has the institutional-import capacity to file the Anktiva NOC alongside BCG procurement. Aga Khan University Hospital, Karachi, runs a Section of Urology with a multidisciplinary bladder-cancer clinic (hospitals.aku.edu) and routinely manages cystoscopic surveillance and intravesical-therapy cycles. Shaukat Khanum Memorial Cancer Hospital, Lahore, treats bladder cancer through its Urology and Surgical Oncology cooperation, with the same service available at the Peshawar and Karachi campuses (shaukatkhanum.org.pk). The Jinnah Postgraduate Medical Centre Department of Urology in Karachi and the Indus Hospital and Health Network surgical services (indushospital.org.pk) round out the realistic dispensing list for cystoscopy-driven BCG-unresponsive NMIBC cases.

What Anktiva costs in Pakistan

The US wholesale acquisition cost for Anktiva is approximately USD 89,200 per induction course (six weekly instillations) and approximately USD 245,000 per full first-year course including maintenance instillations per ImmunityBio launch disclosures and Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Cumulative cost depends on the cystoscopic-response-driven maintenance schedule (continued instillations every three months for the first year then reduced cadence for up to 37 months per the protocol). No public PKR benchmark for Anktiva on the DRAP Maximum Retail Price database or in Pakistani patient-organisation reporting has been observed as of 2026-06-01; do not estimate. Price snapshot: 2026-06-01. Cost layers above the drug cost include validated cold-chain international logistics into Pakistan (2 to 8 degrees Celsius with continuous monitoring, low to mid four-figure USD range per shipment cycle), DRAP NOC and Federal Board of Revenue customs fees (nominal relative to drug cost), the dispensing hospital's outpatient urology procedure fee for intravesical instillation, and the Reserve Meds concierge fee itemised separately on every firm quote. ImmunityBio US patient services do not extend to Pakistani residents. Co-administered BCG supply availability is a separate planning constraint and is sourced through the same DRAP institutional channel.

Funding and access barriers for Anktiva in Pakistan

The pivotal funding argument on a Pakistani Anktiva case is the cystectomy-alternative framing: the realistic comparator from the patient's perspective is radical cystectomy plus urinary diversion plus adjuvant pathway, a major surgical course with its own continuing costs, and the Anktiva-plus-BCG bladder-preserving alternative now has an FDA-labelled efficacy signal in BCG-unresponsive disease. Private insurers active in Pakistan (Jubilee Life Insurance, EFU Life, State Life Insurance Corporation, Adamjee Life) do not list unlicensed drugs on retail formularies, but on group corporate policies the comparator-cost case is the one that opens pre-authorisation discussions, particularly where the policy already covers cystectomy. The Sehat Sahulat Programme at pmhealthprogramme.gov.pk remains scoped to in-network empaneled inpatient care rather than imported intravesical biologics, and the Khyber Pakhtunkhwa Sehat Card Plus, while the broadest provincial cover, has not historically reimbursed imported intravesical immunotherapy. Pakistan Bait-ul-Mal grants at pbm.gov.pk on the cancer track can defray a cycle or two of induction. With out-of-pocket spend persistently above 50 percent of Pakistani health expenditure per the World Bank series (data.worldbank.org), the working pattern on Anktiva is patient self-pay layered with SIUT or SKMCH charity assistance and family-and-diaspora remittance. The class-specific access barrier on Anktiva is not regulatory and not the drug invoice in isolation; it is the requirement for paired intravesical BCG supply, which has cycled through periodic global manufacturing shortages, and SIUT and SKMCH urology pharmacies typically secure the BCG induction-and-maintenance allocation in advance of filing the Anktiva NOC.

Recent regulatory and access news for Anktiva

DRAP published the consolidated Guidance Document for Applicants on Import and Export Permissions of Therapeutic Goods (QALT/GL/IP/004) covering personal-use, institutional, and donation imports, the current operative reference for any Anktiva NOC application; full notice at dra.gov.pk regulatory updates. The Federal Cabinet of Pakistan approved an exemption for the import of unregistered drugs in defined public-interest cases under Section 23 of the Drugs Act 1976, broadening the institutional-import lane for high-cost rare and oncology drugs not commercially available in Pakistan, reported at Express Tribune. On the manufacturer side, ImmunityBio continues post-marketing follow-up of the QUILT-3.032 cohort and label-expansion programmes for additional bladder-cancer subtypes; no DRAP-specific bulletin for Anktiva over the last 12 months has been observed as of 2026-06-01.

Where Reserve Meds fits in Anktiva cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace DRAP, and we do not replace your dispensing pharmacy. For Anktiva specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Pakistan, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Anktiva case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the DRAP application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Anktiva is delivered intravesically in combination with BCG on a defined induction-and-maintenance schedule; cystoscopic surveillance and BCG availability govern treatment continuity.

Next step

If your Pakistani physician has prescribed Anktiva and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Anktiva case Or message us on WhatsApp